VITRA 2 RECEIVES APPROVAL FROM THE FDA

  • 12/06/2019
Download PDF

VITRA 2 RECEIVES APPROVAL FROM THE FDA

  • 12/06/2019
Download PDF

VITRA 2 RECEIVES APPROVAL FROM THE FDA

  • 12/06/2019
Download PDF

Quantel Medical announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the Vitra 2® photocoagulator.

Vitra 2® includes all the key elements that have made the success of the Vitra photocoagulator such as reliability, compactness and versatility. It also features a wide a range of improvements and new functionalities:

Technology:
Vitra 2® features a new generation of optimized laser cavity with an increased max power level. It is also now compatible with SingleSpot and MultiSpot technologies.

All-new clinically oriented software:
Vitra 2® features an easy to use clinically oriented software interface simplifying the treatment procedures and the doctors’ workflow thanks to printable treatment reports.

Wide range of delivery systems:
Vitra 2® is compatible with Haag Streit and Zeiss types slit lamps, with Quantel Medical YAG and YAG/SLT lasers and can be connected to a wide range of delivery systems (operating Microscopes, laser indirect ophthalmoscopes and laser probes).

After a successful career spanning more than 13 years and with more than 3000 units sold worldwide, Quantel Medical is proud to announce the renewal of its 532nm flagship Vitra photocoagulator. We are very excited to bring our new 532nm laser to ophthalmologists and their patients. Thanks to its flexibility and its ease of use, we are sure that more and more surgeons will embrace the MultiSpot technology delivery mode and its associated treatments benefits for retinal photocoagulation.

Jean-Marc Gendre, CEO Quantel Medical
Already launched in Europe in 2018, the Vitra 2® laser has already met its market across the various countries where it is commercialized.

For more information about Vitra 2®, visit our website for healthcare professionnals:

Learn more
The information collected through this form is recorded and transmitted to the relevant LUMIBIRD MEDICAL departments and enables us to send you any reply to a request via the contact form. The legal basis for the processing is consent. The data collected are kept for 3 years in digital format and are only transmitted to LUMIBIRD MEDICAL’s internal departments as well as to our distributors and subsidiaries. You have a right to access, rectify, contest, limit the processing of and erase data. For more information on the use of your data and your rights resulting from the amended French Data Protection Act and the GDPR, please consult our data protection policy or contact our Data Protection Officer at privacy@lumibird.com.
For more informations on how Quantel Medical uses your data, please see our Terms and conditions.